Medium: Are artificial sweeteners harmful? The truth
UC expert describes a link between artificial sweeteners and headaches
An article posted on Medium.com takes a deep dive into artificial sweeteners. The story examines what they are, takes a look at the different types of sweeteners that are on the market and the various effects they have on a person's health.
Included in those health impacts are weight gain, depression, digestive issues and headaches.
The article quotes Vincent Martin, MD, professor in the Department of Internal Medicine at the UC College of Medicine, director of the Headache and Facial Pain Center at the UC Gardner Neuroscience Institute who has analyzed research on the connection between artificial sweeteners and headaches.
Vincent Martin, MD, professor in the Department of Internal Medicine at the UC College of Medicine, director of the Headache and Facial Pain Center at the UC Gardner Neuroscience Institute /Photo/Colleen Kelley/UC Marketing + Brand
The article in Medium.com reports artificial sweeteners, like aspartame, have been shown to cause headaches in a small percentage of people. People who have migraines have been shown to be more susceptible to getting headaches after consuming artificial sweeteners.
Referring to that research, Martin concluded that “Two of the three randomized studies involving aspartame have shown a positive correlation between the sweetener and headache.”
However, he also says that “… you really have to ingest large quantities of aspartame to generate headache. It might be two to three liters of diet soda per day. It also requires a prolonged exposure. A headache may not occur with one drink.”
Lead photo/Myriam Zilles/Unsplash
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.